Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
15
×
national blog main
texas blog main
15
×
texas top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
fda
cancer
clinical trials
novartis
eli lilly
startups
amgen
crispr
ipo
medical device
medical devices
teva pharmaceutical
venture capital
What
new
15
×
bio
drug
roundup
fda
life
antonio
approval
cancer
companies
drugs
ipo
san
science
sciences
center
class
crispr
genetic
group
isn’t
known
medicine
medicines
migraine
million
plan
plans
remains
testing
therapeutics
wave
won
work
year
accelerator
action
activity
adult
advantages
Language
unset
Current search:
new
×
" life sciences "
×
" texas blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
UT Health San Antonio Plans New Accelerator for Faculty Research
@xconomy.com
5 years ago
GenCure Plans Adult Stem Cell Lab at San Antonio “Innovation Center”
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
San Antonio Develops “Action Plan” to Draw Life Sciences Businesses
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?